. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Mult Scler Relat Disord. 2012 Dec 7;2(2):133–140. doi: 10.1016/j.msard.2012.10.002

Table 1.

Demographics.

	Daclizumab	Non-daclizumab
Patients (n)	26	44
Sex (% females)	58%	68%
Age at baseline, years (median, range)	35, 18–54	39, 19–58
Disease duration at baseline, years (median, range)	4, 0.1–15	8, 0.1–30
EDSS at baseline (median, range)	1.5, 0–5.5	1.5, 0–6.5
Total time on daclizumab, years (median, range)	4.3, 0.4–9.5	N/A
Normalized brain volume (mean±SD)	0.785±0.032	0.787±0.034
Scans per patient (median, range)	38, 5–55	14, 1–25
Total duration of follow-up, years (median, range)	6.7 (1.9–10.5)	5.4 (1.0–9.4)